Inventor · disambiguated record
Marc Gitzinger
Also filed as: GITZINGER MARC
13 granted patents·10 pending applications·28 citations·filing 2010–2025
87Inventor score
Top patents by PatentIndex Score
23 records- 0189US11207305B2Antibiotic combination therapiesBioVersys AG·Filed 2020·Granted Dec 28, 2021·2 cites·20 claims
- 0289US8912329B2Composition for treatment of tuberculosisSCHOENMAKERS RONALD·Filed 2010·Granted Dec 16, 2014·21 cites·15 claims
- 0388US11766425B2Antibiotic combination therapiesBioVersys AG·Filed 2021·Granted Sep 26, 2023·1 cites·21 claims
- 0486US12403133B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2024·Granted Sep 2, 2025·0 cites·20 claims
- 0584US12257241B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2023·Granted Mar 25, 2025·0 cites·24 claims
- 0682US2025360115A1Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2025·Application pending·0 cites
- 0780US11833139B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2022·Granted Dec 5, 2023·0 cites·16 claims
- 0879US11903934B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2022·Granted Feb 20, 2024·0 cites·10 claims
- 0978US2025281469A1Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2025·Application pending·0 cites
- 1072US11351158B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2020·Granted Jun 7, 2022·0 cites·21 claims
- 1171US11344537B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2020·Granted May 31, 2022·0 cites·16 claims
- 1270US12370184B2Antibiotic combination therapiesBioVersys AG·Filed 2023·Granted Jul 29, 2025·0 cites·20 claims
- 1370US9682079B2Composition for treatment of pathogens that are resistant to tetracyclinesBioVersys AG·Filed 2014·Granted Jun 20, 2017·4 cites·10 claims
- 1462US2025213575A18-heterocyclic-3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivatives as anti-bacterialsBioVersys AG·Filed 2023·Application pending·0 cites
- 1562US2025376472A13-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivativesBioVersys AG·Filed 2023·Application pending·0 cites
- 1661US2023364065A1Antibiotic combination therapiesBioVersys AG·Filed 2022·Application pending·0 cites
- 1761US2025101039A1Rifamycin derivatives for the treatment of diseasesBioVersys AG·Filed 2023·Application pending·0 cites
- 1860US2025051356A1Rifabutin analogs for the treatment of diseaseBioVersys AG·Filed 2022·Application pending·0 cites
- 1960US2025235434A1Rifabutin analogs for the treatment of diseaseBioVersys AG·Filed 2023·Application pending·0 cites
- 2048US12509462B23-(phenylsulfonyl)-[1,2,3]triazolo[1,5A]quinazolin-5(4H)-one derivativesBioVersys AG·Filed 2019·Granted Dec 30, 2025·0 cites·18 claims
- 2145US2025360114A1Intravenous rifabutin formulation and methods of makingBioVersys AG·Filed 2025·Application pending·0 cites
- 2243US2021222181A1Bacterial vectors for genetic manipulation of bacteriaBioVersys AG·Filed 2019·Application pending·0 cites
- 2335US8653046B2Controlling transgene expression across the skinFUSSENEGGER MARTIN·Filed 2010·Granted Feb 18, 2014·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Marc Gitzinger files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →